AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of ARS 316.70 trillion. The enterprise value is 350.03 trillion.

Market Cap	316.70T
Enterprise Value	350.03T

Important Dates

The last earnings date was Tuesday, July 29, 2025.

Earnings Date	Jul 29, 2025
Ex-Dividend Date	Aug 8, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.06%
Shares Change (QoQ)	-0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 32.04 and the forward PE ratio is 16.09.

PE Ratio	32.04
Forward PE	16.09
PS Ratio	4.70
PB Ratio	5.93
P/TBV Ratio	n/a
P/FCF Ratio	23.78
P/OCF Ratio	19.85
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.00, with an EV/FCF ratio of 26.28.

EV / Earnings	35.41
EV / Sales	4.82
EV / EBITDA	14.00
EV / EBIT	19.00
EV / FCF	26.28

Financial Position

The company has a current ratio of 0.86, with a Debt / Equity ratio of 0.74.

Current Ratio	0.86
Quick Ratio	0.66
Debt / Equity	0.74
Debt / EBITDA	1.69
Debt / FCF	2.95
Interest Coverage	10.77

Financial Efficiency

Return on equity (ROE) is 19.67% and return on invested capital (ROIC) is 11.88%.

Return on Equity (ROE)	19.67%
Return on Assets (ROA)	8.28%
Return on Invested Capital (ROIC)	11.88%
Return on Capital Employed (ROCE)	18.19%
Revenue Per Employee	714.02M
Profits Per Employee	104.83M
Employee Count	94,300
Asset Turnover	0.52
Inventory Turnover	1.65

Taxes

In the past 12 months, AstraZeneca has paid 2.05 trillion in taxes.

Income Tax	2.05T
Effective Tax Rate	17.17%

Stock Price Statistics

The stock price has decreased by -3.02% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-3.02%
50-Day Moving Average	45,471.50
200-Day Moving Average	42,595.88
Relative Strength Index (RSI)	67.17
Average Volume (20 Days)	514

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of ARS 67.33 trillion and earned 9.89 trillion in profits. Earnings per share was 6,326.07.

Revenue	67.33T
Gross Profit	55.39T
Operating Income	17.10T
Pretax Income	11.94T
Net Income	9.89T
EBITDA	22.79T
EBIT	17.10T
Earnings Per Share (EPS)	6,326.07

Full Income Statement

Balance Sheet

The company has 8.47 trillion in cash and 39.25 trillion in debt, giving a net cash position of -30,782.80 billion.

Cash & Cash Equivalents	8.47T
Total Debt	39.25T
Net Cash	-30,782.80B
Net Cash Per Share	n/a
Equity (Book Value)	53.40T
Book Value Per Share	34,381.70
Working Capital	-5,478.24B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 15.96 trillion and capital expenditures -2,637.23 billion, giving a free cash flow of 13.32 trillion.

Operating Cash Flow	15.96T
Capital Expenditures	-2,637.23B
Free Cash Flow	13.32T
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.26%, with operating and profit margins of 25.40% and 14.68%.

Gross Margin	82.26%
Operating Margin	25.40%
Pretax Margin	17.74%
Profit Margin	14.68%
EBITDA Margin	33.85%
EBIT Margin	25.40%
FCF Margin	19.78%

Dividends & Yields

This stock pays an annual dividend of 834.84, which amounts to a dividend yield of 1.62%.

Dividend Per Share	834.84
Dividend Yield	1.62%
Dividend Growth (YoY)	45.86%
Years of Dividend Growth	3
Payout Ratio	59.51%
Buyback Yield	-0.06%
Shareholder Yield	1.55%
Earnings Yield	3.12%
FCF Yield	4.21%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.98
Piotroski F-Score	6